全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Sickle Crisis Precipitated by Pneumonia: A Diagnostic and Therapeutic Challenge

DOI: 10.4236/jbm.2025.131021, PP. 255-263

Keywords: Sickle Cell Anemia, Sickle Cell Crisis, Pain Management, Pneumonia, Hydroxyurea

Full-Text   Cite this paper   Add to My Lib

Abstract:

Sickle cell anemia (SCA) is a prevalent genetic disorder primarily affecting individuals of African descent and populations in malaria-endemic regions, with significant global public health implications. Sickle cell crises are their most common acute complication, characterized by episodes of intense pain and systemic manifestations that impair quality of life and impose a high healthcare burden. We present the case of a 19-year-old male diagnosed with SCA since the age of two, who developed a sickle cell crisis precipitated by right basal pneumonia. The patient exhibited sudden-onset, cyclic lumbar pain with progressive dyspnea. Initial management included multimodal pain control, volume optimization, and targeted antimicrobial therapy to achieve clinical stabilization. This case underscores the importance of a comprehensive approach to managing sickle cell crises, addressing both symptomatic relief and the prevention and treatment of complications. It also highlights the need for public health strategies promoting early diagnosis, access to disease-modifying therapies such as hydroxyurea, and interdisciplinary follow-up to mitigate the socioeconomic and clinical impact of SCA.

References

[1]  Kato, G.J., Piel, F.B., Reid, C.D., Gaston, M.H., Ohene-Frempong, K., Krishnamurti, L., et al. (2018) Sickle Cell Disease. Nature Reviews Disease Primers, 4, Article No. 18010.
https://doi.org/10.1038/nrdp.2018.10
[2]  Williams, T.N. and Thein, S.L. (2018) Sickle Cell Anemia and Its Phenotypes. Annual Review of Genomics and Human Genetics, 19, 113-147.
https://doi.org/10.1146/annurev-genom-083117-021320
[3]  Kavanagh, P.L., Fasipe, T.A. and Wun, T. (2022) Sickle Cell Disease. Journal of the American Medical Association, 328, 57-68.
https://doi.org/10.1001/jama.2022.10233
[4]  Ayala Viloria, A.J., González Torres, H.J. and David Tarud, G.J. (2016) Sickle Cell Anemia: A Review. Salud Uninorte, 32, 513-527.
https://doi.org/10.14482/sun.32.2.9750
[5]  Egesa, W.I., Nakalema, G., Waibi, W.M., Turyasiima, M., Amuje, E., Kiconco, G., et al. (2022) Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond. International Journal of Pediatrics, 2022, 1-26.
https://doi.org/10.1155/2022/3885979
[6]  Ware, R.E., de Montalembert, M., Tshilolo, L. and Abboud, M.R. (2017) Sickle Cell Disease. The Lancet, 390, 311-323.
https://doi.org/10.1016/s0140-6736(17)30193-9
[7]  Piccin, A., Murphy, C., Eakins, E., Rondinelli, M.B., Daves, M., Vecchiato, C., et al. (2019) Insight into the Complex Pathophysiology of Sickle Cell Anaemia and Possible Treatment. European Journal of Haematology, 102, 319-330.
https://doi.org/10.1111/ejh.13212
[8]  Takaoka, K., Cyril, A.C., Jinesh, S. and Radhakrishnan, R. (2020) Mechanisms of Pain in Sickle Cell Disease. British Journal of Pain, 15, 213-220.
https://doi.org/10.1177/2049463720920682
[9]  da Silva Araújo, A., Silva Pinto, A.C., de Castro Lobo, C.L., Figueiredo, M.S., Menosi Gualandro, S.F., Olalla Saad, S.T., et al. (2024) Sickle Cell Disease in Brazil: Current Management. Hemoglobin, 48, 218-230.
https://doi.org/10.1080/03630269.2024.2344790
[10]  Carcao, M. and Cook, D.R. (2012) Sickle Cell Disease: Managing Acute Painful Episodes in Hospital. National Institute for Health and Care Excellence.
[11]  Ochocinski, D., Dalal, M., Black, L.V., Carr, S., Lew, J., Sullivan, K., et al. (2020) Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review. Frontiers in Pediatrics, 8, Article 38.
https://doi.org/10.3389/fped.2020.00038
[12]  Pinto, V.M., Balocco, M., Quintino, S. and Forni, G.L. (2019) Sickle Cell Disease: A Review for the Internist. Internal and Emergency Medicine, 14, 1051-1064.
https://doi.org/10.1007/s11739-019-02160-x
[13]  Novelli, E.M. and Gladwin, M.T. (2016) Crises in Sickle Cell Disease. Chest, 149, 1082-1093.
https://doi.org/10.1016/j.chest.2015.12.016
[14]  Sundd, P., Gladwin, M.T. and Novelli, E.M. (2019) Pathophysiology of Sickle Cell Disease. Annual Review of Pathology: Mechanisms of Disease, 14, 263-292.
https://doi.org/10.1146/annurev-pathmechdis-012418-012838
[15]  Ogu, U.O., Badamosi, N.U., Camacho, P.E., Freire, A.X. and Adams-Graves, P. (2021) Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome. Journal of Blood Medicine, 12, 101-114.
https://doi.org/10.2147/jbm.s291394
[16]  Batra, N., Acharya, S., Ahuja, A. and Saboo, K. (2024) Guarding Health: A Comprehensive Review of Nosocomial Infections in Sickle Cell Anemia, a Multifaceted Approach to Prevention. Cureus, 16, e53224.
https://doi.org/10.7759/cureus.53224
[17]  Gaut, D., Jones, J., Chen, C., Ghafouri, S., Leng, M. and Quinn, R. (2020) Outcomes Related to Intravenous Fluid Administration in Sickle Cell Patients during Vaso-Occlusive Crisis. Annals of Hematology, 99, 1217-1223.
https://doi.org/10.1007/s00277-020-04050-1
[18]  Gaartman, A.E., Sayedi, A.K., Gerritsma, J.J., de Back, T.R., van Tuijn, C.F., Tang, M.W., et al. (2021) Fluid Overload Due to Intravenous Fluid Therapy for Vaso-Occlusive Crisis in Sickle Cell Disease: Incidence and Risk Factors. British Journal of Haematology, 194, 899-907.
https://doi.org/10.1111/bjh.17696
[19]  Patel, D.K., Mohapatra, M.K., Thomas, A.G., Patel, S. and Purohit, P. (2014) Procalcitonin as a Biomarker of Bacterial Infection in Sickle Cell Vaso-Occlusive Crisis. Mediterranean Journal of Hematology and Infectious Diseases, 6, e2014018.
https://doi.org/10.4084/mjhid.2014.018
[20]  Maharaj, S. and Chang, S. (2022) Procalcitonin as a Diagnostic Marker for Infection in Sickle Cell Disease. Expert Review of Hematology, 15, 559-564.
https://doi.org/10.1080/17474086.2022.2079490
[21]  Cheminet, G., Mekontso-Dessap, A., et al. (2022) Syndrome thoracique aigu chez les patients drépanocytaires adultes. La Revue de Médecine Interne, 43, 470-478.
https://doi.org/10.1016/j.revmed.2022.04.019
[22]  Brandow, A.M., Carroll, C.P., Creary, S., Edwards-Elliott, R., Glassberg, J., Hurley, R.W., et al. (2020) American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic Pain. Blood Advances, 4, 2656-2701.
https://doi.org/10.1182/bloodadvances.2020001851
[23]  Rankine-Mullings, A.E. and Nevitt, S.J. (2022) Hydroxyurea (Hydroxycarbamide) for Sickle Cell Disease. Cochrane Database of Systematic Reviews, 2022, Article No. CD002202.
https://doi.org/10.1002/14651858.cd002202.pub3
[24]  Ataga, K.I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., et al. (2017) Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. New England Journal of Medicine, 376, 429-439.
https://doi.org/10.1056/nejmoa1611770

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133